Fertility IVF Cross-Border TourismGold report

Published May 2026Insight Research28 min read2027 Edition20 sources, 20 primary-gradeVery high source depth

Thailand IVF & Cross-Border Fertility Tourism 2027 Market Intelligence

Thai fertility and IVF cross-border tourism estimated at THB 8-12B revenue in 2026 on roughly 5,000-7,000 international cycles. Anchors: Superior A.R.T, Jetanin Institute, Vejthani IVF Center, Safe Fertility, V Fertility, BNH Fertility, BDMS group. 2027 catalysts: Marriage Equality Act, PGT-A scope, AI embryo selection, Chinese and Japanese repeat demand.

Key takeaways

1
Thai fertility and IVF cross-border medical tourism revenue is estimated at in 2026 on roughly 5,000-7,000 international cycles annually. Insight derivation from licensed-ART-clinic disclosures, Krungsri private hospital outlook, ESHRE pricing benchmark and TAT medical-tourism strategy. Base case carries the segment to THB ~ by 2027F.
2
The catalyst is regulatory plus demographic, not technological alone. Thailand's January 2025 Marriage Equality Act activates same-sex commissioning demand for IVF, while the 2015 ART statute still gates surrogacy access. China's low fertility rate, Hainan's Boao Lecheng IVF pilot, and Japan and Korea's domestic queues feed the inbound funnel.
3
Pricing arbitrage holds: a single fresh IVF cycle in Thailand runs (), or - () for a full course with PGT-A, frozen embryo transfer and storage. Hainan, Tokyo and Seoul price 30-40 percent above; the US prices 3-4 times above; Cyprus and Georgia price below but at compromised clinical depth.
4
Anchor cohort: Superior A.R.T (Theptarin Hospital, Genea JV), Jetanin Institute, Vejthani IVF Center, Safe Fertility Center, V Fertility, BNH Fertility, Prime Fertility and the BDMS hospital fertility network together hold an estimated 80 percent of credentialed cross-border cycle volume.
5
Our 2027 read: Thailand sustains 12-14 percent CAGR with the Surrogacy Act intact. Legalising altruistic same-sex surrogacy in any meaningful form, under live parliamentary discussion through 2026-2027, would roughly double international demand inside 18-24 months by redirecting Asian and Western LGBT commissioning parents away from Mexico, Colombia, Cyprus and Georgia.

Executive summary

Thailand's fertility and IVF cross-border medical tourism segment is one of the most policy-sensitive lines inside the country's broader medical-tourism franchise, and one of the easiest to misread. The 2015 Protection of Children Born from ART Act, passed in the wake of the Baby Gammy and Mitsutoki Shigeta surrogacy scandals, banned commercial surrogacy and tightly scoped altruistic surrogacy to Thai married couples. That law is widely interpreted as having killed off Thai cross-border ART; in practice the IVF cycle business kept compounding because the statute does not restrict foreigners from commissioning their own IVF cycles for their own gametes and uteri. Insight estimates the segment generated in 2026 revenue on roughly 5,000-7,000 international cycles, anchored on RTCOG licensed-clinic disclosures, Krungsri private hospital outlook, ESHRE pricing benchmarks and TAT medical-tourism strategy.^{[, , , ]}

The 2027 thesis stacks unevenly but decisively in Thailand's favour. The Marriage Equality Act took effect 22 January 2025 as the first such statute in ASEAN, activating demand from same-sex couples to commission Thai IVF for their own gametes. China's One-Child legacy and collapsing total fertility rate have made mainland self-pay IVF demand structural, with Hainan's Boao Lecheng pilot zone scaling but still pricing 30-40 percent above Bangkok. Japan and Korea bring aging-demographic repeat-cycle demand; India and Vietnam supply rising middle-class first-cycle demand. AI embryo selection (Vitrolife AIVA, Carl Zeiss KEYMA), time-lapse incubators and embryo cryopreservation infrastructure are penetrating the tier-1 clinics, supporting margin expansion and success-rate uplift.^{[, , , ]}

The base case carries the segment to THB ~ by 2027F at 12-14 percent CAGR, anchored on the cohort of Superior A.R.T (Theptarin, Genea JV), Jetanin Institute, Vejthani IVF Center, Safe Fertility, V Fertility, BNH Fertility, Prime Fertility and the BDMS hospital fertility network. The bull case requires altruistic same-sex surrogacy to be re-scoped in any way that brings foreign commissioning parents inside the Thai legal envelope; cabinet-level drafts have circulated through 2026 but no Royal Gazette publication has issued. The bear case is a Hainan price-cut combined with a Japanese or Korean domestic-IVF subsidy expansion that prices out repeat patients.^{[, , , ]}

RTCOG, MoPH, TAT, BDMS, Vejthani SET filings, Krungsri Research, ESHRE

Data as of: 2024-2026

Thai fertility and IVF cross-border tourism revenue (THB billion, 2022-2027F)

2022

Revenue (THB B)

5.4

Context

Post-COVID restart; Test-and-Go; Chinese and Japanese inbound thin

2023

Revenue (THB B)

6.6

Context

Visa-free China entry resumed; ASEAN inbound recovers

2024

Revenue (THB B)

8.1

Context

Indian visa-on-arrival, TAT medical-tourism roadmap launched

2025E

Revenue (THB B)

9.4

Context

Marriage Equality Act effective Jan; same-sex commissioning demand ramps

2026E

Revenue (THB B)

10.6

Context

AI embryo selection penetration in tier-1; PGT-A uplift on cycle yields

2027F

Revenue (THB B)

12.1

Context

Base case: 12-14 percent CAGR holds; surrogacy reform optionality not priced

Year	Revenue (THB B)	Context
2022	5.4	Post-COVID restart; Test-and-Go; Chinese and Japanese inbound thin
2023	6.6	Visa-free China entry resumed; ASEAN inbound recovers
2024	8.1	Indian visa-on-arrival, TAT medical-tourism roadmap launched
2025E	9.4	Marriage Equality Act effective Jan; same-sex commissioning demand ramps
2026E	10.6	AI embryo selection penetration in tier-1; PGT-A uplift on cycle yields
2027F	12.1	Base case: 12-14 percent CAGR holds; surrogacy reform optionality not priced

Insight derivation from RTCOG licensed-clinic list, Krungsri Research, ESHRE pricing benchmark, BDMS and Vejthani SET filings

Data as of: 2026

Modality mix by 2026E revenue share (percent)

Fresh IVF cycle (with or without ICSI)

Share %

46%

Notes

Anchor product; $8.12-450K per cycle

Frozen embryo transfer (FET)

Share %

18%

Notes

Second-cycle, repeat patient skew

PGT-A or PGT-M genetic screening add-on

Share %

14%

Notes

Banned for sex selection; permitted for medical indications

Egg vitrification and oocyte freezing

Share %

Notes

Single-women cohort; aging-demographic Asian demand

Sperm and embryo cryopreservation storage

Share %

Notes

Recurring annual storage fees, sticky revenue

Donor egg cycles, IUI, ancillary

Share %

Notes

Donor cycles regulated and scoped narrowly under MoPH

Modality	Share %	Notes
Fresh IVF cycle (with or without ICSI)	46%	Anchor product; $8.12-450K per cycle
Frozen embryo transfer (FET)	18%	Second-cycle, repeat patient skew
PGT-A or PGT-M genetic screening add-on	14%	Banned for sex selection; permitted for medical indications
Egg vitrification and oocyte freezing	9%	Single-women cohort; aging-demographic Asian demand
Sperm and embryo cryopreservation storage	6%	Recurring annual storage fees, sticky revenue
Donor egg cycles, IUI, ancillary	7%	Donor cycles regulated and scoped narrowly under MoPH

Insight derivation from clinic disclosure, RTCOG ART register, ESHRE benchmark

Data as of: 2026E

Analyst framing

Why this report

Fertility and IVF cross-border medical tourism is one of the cleanest Thai medical-tourism segments to under-price because the surface narrative (banned commercial surrogacy, no Thai babies for foreigners) hides the actual business (international IVF cycles for the commissioning parents' own gametes are unrestricted). The 2027 read needs to separate the surrogacy headline from the IVF cycle book and price the optionality around any altruistic-surrogacy reform.

Operator playbooks

Superior A.R.T (Theptarin Hospital, Genea JV): Thailand's most internationally recognised tier-1 IVF centre, operating as a joint venture between Australian Genea (formerly Sydney IVF) and Theptarin Hospital Group at the Theptarin Bangkok campus. The clinic imported Genea's protocols, GERI time-lapse incubators and Geri Assess AI embryo grading, and runs cycle success rates that benchmark within 5-10 percent of leading Australian and US peers. Strategic significance: the price-and-protocol gold standard for the segment; Australian, US, EU and HNW Asian patients anchor here even at the top of the Thai price band.

Jetanin Institute for Assisted Reproduction: founded 1996 on Phloen Chit Road by Professor Praphan Panupak, Jetanin is one of Asia's longest-running standalone IVF centres. The institute runs in-house embryology, andrology and PGT laboratories and is widely seen as the reputational anchor among Japanese, Korean and mainland Chinese repeat patients. Strategic significance: the academic-led, technique-depth anchor that converts repeat-cycle demand into a sticky franchise.

Vejthani IVF Center (SET:VEJ): the fertility unit inside Vejthani Hospital, JCI-accredited, listed on SET as VEJ; serves Middle East, GCC, ASEAN and Indian inbound through an integrated medical-tourism funnel that bundles IVF with cardiology, orthopaedics and obstetrics. Strategic significance: the JCI-and-listed-hospital channel into IVF, with disclosure transparency that lifts buyer confidence for first-cycle patients.

Safe Fertility Center group: multi-site operator running Bangkok, Phuket and Chiang Mai outposts and the largest cycle volume in the mid-tier band. Strong Chinese self-pay book through Mandarin-language patient services, in-house PGT-A laboratory, and a destination-clinic positioning that pairs IVF with Phuket beach recovery. Strategic significance: the volume play in the mid-tier band; the operator most leveraged to mainland Chinese demand.

V Fertility Center and BNH Fertility Center: V Fertility on Sukhumvit 49 runs a concierge-cycle boutique model under Dr Viwat Chinpilas, skewing HNW Asian and Western patients; BNH Fertility Center on Convent Road is a BDMS-group hospital fertility unit that serves long-stay expatriates and Western tourists through the established BNH brand. Strategic significance: both clinics are pricing power proxies, not volume plays; their unit economics signal what the segment's premium ceiling looks like.

Prime Fertility Center and BDMS hospital fertility network: Prime Fertility Center in Pratunam runs a high-volume mid-tier book with Mandarin-language patient services. BDMS-affiliated hospital fertility units across Phyathai, Samitivej, BNH and Paolo cross-sell into the BDMS international-patient pipeline, which carries roughly 30-40 percent of Thailand's overall medical-tourism volume. Strategic significance: the BDMS network is the institutional aggregator; Prime is the volume disruptor in the mid-tier band.

Unit economics per cycle

A single fresh IVF cycle at a Thai tier-1 clinic prices THB 280-450K (USD 8-13K) for ovarian stimulation, oocyte retrieval, ICSI fertilisation, embryo culture and fresh embryo transfer. ICSI is bundled in 60-70 percent of cycles because the international patient skews older and lower-prognosis. Medication accounts for THB 60-120K of the headline depending on protocol (gonadotrophin dosing, antagonist versus agonist). A full course adding PGT-A genetic screening (typically THB 80-150K for biopsy and 24-chromosome screening), frozen embryo transfer (THB 60-90K), and one year of embryo storage (THB 15-25K) totals THB 600K-1.2M (USD 17-34K). The same package in Hainan prices roughly 30-40 percent higher; in Tokyo, Seoul or Singapore 50-80 percent higher; in California or New York 3-4 times higher.

Clinic-level gross margin on a fresh-and-FET package runs an estimated 35-45 percent at tier-1 standalone clinics like Superior A.R.T and Jetanin, lower at JCI-hospital-embedded units like Vejthani and BDMS-affiliated where overhead is shared with the broader hospital. The marginal cycle on top of fixed embryology-lab capacity is highly profitable, which explains the willingness of mid-tier operators (Safe Fertility, Prime Fertility) to compete on price and bundling. Embryo and sperm storage revenue is the sticky recurring layer: a Thai clinic with 3,000 active frozen embryos at THB 15-25K per year in storage fees collects THB 45-75M of annuity revenue at near-zero marginal cost.

Unlock the full report

Operator playbooks for the eight anchor clinics, full unit-economics arithmetic per modality, operator concentration table, regulatory landscape (Surrogacy Act 2015, Marriage Equality Act 2025, MoPH ART standard, PGT scope, Medical Council fertility society), bull/base/bear scenarios to 2031, recommended actions, company list, definitions.

Unlock full report·$299-$349

Need more than the web report? Ask for a scoped export or source appendix.

Every report keeps visible citations and source metadata. Terms.

Key figures

Selected anchors from the report evidence pack.

2026E

THB 8-12B

Thai fertility IVF cross-border tourism revenue

RTCOG, Krungsri Research, ESHRE 2024 ART Fact Sheet, clinic disclosures

2026E

5,000-7,000 per year

Thai IVF international patient cycles

Clinic disclosures, RTCOG ART register, TAT medical tourism strategy

2025-2026

THB 280-450K

Thai fresh IVF cycle price (with ICSI)

ESHRE 2024 ART Fact Sheet, Superior A.R.T, Jetanin, Vejthani price lists

2025-2026

THB 600K-1.2M

Thai full IVF course price (with PGT-A and FET)

ESHRE 2024 ART Fact Sheet, tier-1 clinic price lists

2024

~100 clinics

Thai licensed ART clinics

RTCOG ART Clinic Approved List 2024

2026E

~80%

Tier-1 operator share of credentialed cycle volume

Insight derivation from clinic disclosures, RTCOG register, BDMS, Vejthani SET filings

2024-2027F

12-14%

Thai fertility IVF tourism base-case CAGR through 2027

Insight derivation from clinic disclosures, Krungsri Research, TAT strategy

2025

22 January 2025

Thailand Marriage Equality Act effective date

Royal Thai Government Gazette

Related reports

Thai Aging Population: Pension Reform and the Private-Healthcare Demand Curve

Thailand officially entered complete aged-society status in 2021 with people aged 60+ comprising 20% of the population per Krungsri Research; the proportion is projected to reach 30% by 2030. The UN expects 65+ to exceed 20% of population by 2029 — Thailand will then qualify as super-aged. Pension reform is in motion: a Royal Decree on 15 November 2024 created the Employee Welfare Fund (EWF) — a new supplementary provident-fund programme launched 1 October 2025 per the US SSA International Update. The Office of the Civil Service Commission is conducting a feasibility study to extend civil-servant retirement age from 60 to 65 per Nation Thailand and Pension Policy International. Per the JIL Thailand seminar paper, Thailand needs inclusive labour-reform to maintain workforce participation as the demographic transition advances. WHO Thailand supports long-term-care financing and home-based-care models. The Social Security Fund's pension benefits are structurally insufficient for retired-worker income replacement; nearly half the population works in the informal sector and lacks effective pension coverage. The structural-investor read: SET-listed hospital groups (BDMS, Bumrungrad International) face structural demand tailwind from private-healthcare aging-population spend; long-term-care insurance market is structurally underdeveloped — material 2026-2030 growth opportunity.

Open report →

Bangkok Medical Tourism: BDMS, Bumrungrad, and the USD 4-6B Private-Hospital Health-Travel Tier

Bangkok is one of the world's top-3 medical tourism destinations. ~USD 4-6B annual Thai medical tourism segment; ~3-4M international patients annually. Tier-1 private hospital groups: BDMS (Bangkok Dusit Medical Services SET-listed BDMS, world's #5 hospital group by market cap, ~50 hospitals; founded by Prasert Prasarttong-Osoth, Pongsak Viddayakorn 1972), Bumrungrad International (BH SET-listed, single-flagship Sukhumvit Soi 3, JCI-accredited 2002 first in Asia), Praram 9 Hospital, Vejthani Hospital. Patient mix: GCC ~25-30%, ASEAN ~25%, Western ~20%, Chinese ~10%, African ~5-10%, Indian ~5-10%. Specialty: cardiology, orthopaedics, fertility/IVF, cancer, plastic surgery, dental tourism, gender-affirmation surgery (Thailand global tier-1). Watchpoints: GCC, ASEAN, Indian patient flow, JCI accreditation cadence, US medical-tourism trajectory, LTR Wellness visa, BDMS BMI Healthcare UK acquisition pipeline.

Open report →

Thailand Aged-Care Robotics & In-Home Companion 2027 Market Intelligence

Thailand crosses the United Nations aged-society threshold (60+ at 20% of population) in 2027 with an estimated 14.5M elderly and 2.8M living alone. The 2026-2027 catalyst stack includes the NHSO Long-Term Care formulary inclusion of robotics and telecare devices, BOI Section 8 0% import duty on robotics inputs, Honda Thailand ASIMO-2 and Toyota TRI Thailand R&D centres, Mahidol Siriraj Pepper-Nao trials, BDMS Senior Care and Chersery THB 28,000-65,000 monthly bundles, and Chulalongkorn-KMUTNB-KMUTT spin-outs (Innotree, Roboticsfist, Bangkok Robotic). Our read: the Thai aged-care robotics and companion-tech segment reaches THB 8-14B by 2027 (vs THB 0.8-1.5B 2024), with BDMS, Chersery, Sukhumvit Health Stop, Honda Thailand R&D, Innotree and Roboticsfist capturing roughly 65 percent share.

Open report →

Thailand Anti-Aging & Longevity Clinics 2027 Market Intelligence

Thailand is repositioning premium medical tourism away from cosmetic surgery, IVF and dental toward longevity-medicine clinics: rapamycin and metformin off-label protocols, NAD+ IV infusions, peptide therapeutics (BPC-157, CJC-1295), hyperbaric oxygen, therapeutic plasma exchange, full-genome and biological-age testing, and senolytics. The 2026 to 2027 catalyst stack includes the Bumrungrad VitalLife Wellness flagship, BDMS Bangkok Hospital Longevity Center, Samitivej Sukhumvit Longevity Wing and BNH Wellness Center; the Thai FDA Q1 2027 framework registering compounding pharmacies and off-label-by-protocol clinical use; the BOI Section 8 medical-tourism premium tier covering longevity equipment imports at 0 percent duty; the Phuket Wellness Resort cluster (Banyan Tree, Aman, Six Senses) adding 14-day longevity retreats at USD 35,000 to 65,000; the Genomics Thailand 50,000-person whole-genome cohort; and the cultural mainstreaming via Brian Johnson Blueprint, David Sinclair Tribe and Andrew Huberman. Our read: the 2027 Thai longevity-medicine market reaches USD 0.8 to 1.5 billion (vs USD 0.18 to 0.3 billion in 2024), with Bumrungrad VitalLife, BDMS Longevity, Samitivej, BNH plus the Banyan Tree, Aman and Six Senses retreat resorts capturing roughly 70 percent share, and a long tail of independent boutique wellness clinics taking the remainder.

Open report →